A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

NCT02720120 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

175

Enrollment

INDUSTRY

Sponsor class

Stopped The overall benefit risk profile of ocrelizumab was not favorable in RA

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Ocrelizumab
DRUG: Placebo

Sponsor

Hoffmann-La Roche